Turning biodiversity
into brain medicine with
computer vision AI.
HELLO@PLATEABIOSCIENCES.COM
DECODING NEUROCHEMICAL FRONTIERS
FOR NEXT-GENERATION BRAIN MEDICINE.
New brain medicine
is hidden in biodiversity.
Platea is built to find it.
The only CNS-native
discovery node embedded
Discovery happens
where the chemistry lives
The only CNS-native
discovery node embedded
Biology is interrogated in-region, decoded
in real time, and advanced only if signal survives CNS-native interpretation.
Each experimental pass informs the next sampling decision.
Two independent evolutionary solutions to nervous system modulation decoded by one engine.
Neuroethnobotanical
Intelligence
Funnel
01.
Millennia of human selection enriched plant chemistry for:
↘ BBB penetration
↘ Behavioral activity
↘ Polypharmacologic CNS modulation
This constitutes a human-encoded CNS prior.
Endemic Amphibian
Neurochemistry
Funnel
02.
Amphibians evolved vertebrate-targeted chemical defenses enriched for:
↘ Ion-channel modulation
↘ GPCR activity
↘ Neuroimmune signaling
↘ Nociception
These compounds represent extreme molecular novelty in CNS-relevant space.
Together, these funnels generate CNS-enriched input space the rest of the industry does not screen.
Together, these funnels generate CNS-enriched input space the rest of the industry does not screen.
AI is embedded directly into phenotypic discovery, not layered on afterward
L1: Evolutionary input selection
Pre-enriched CNS biology enters the system from both
evolutionary funnels.
L2: AI-native behavioral phenotyping (Brian AI™) From raw video, AI learns:
↘ Low-to-High-dimensional behavioral structures
↘ State transitions and network-level dynamics
↘ Modulation vs toxicity separation
↘ CNS-relevant effects before purification or target knowledge
L3: Pharmacobehavioral reference mapping
Unknown biology is triangulated against a growing CNS pharmacological
reference space to:
↘ Infer mechanism
↘ Prioritize novelty
↘ Advance only clean signals
AI interprets phenotype; biology explains it.
AI does not invent chemistry.
The human-interpretable AI
for BRAIN medicine discovery
Behavior-first decoding engine purpose-built for discovery. Developed by the creator of SimBA, the world’s most widely adopted behavioral AI platform. SimBA link
↘ CNS discovery depends on resolving subtle, multidimensional behavioral effects
↘ Most AI systems cannot distinguish:
Therapeutic modulation
Sedation
Toxicity
↘ Brian AI is trained specifically for noisy, polypharmacologic biology
↘ Purpose-built and continuous retraining
on novel evolutionary chemistry
↘ Pharmacobehavioral reference mapping
for mechanism inference
↘ Cloud-native pipelines
for rapid iteration across discovery cycles
↘ >2 million downloads
(SimBA lineage)
↘ Hundreds of peer-reviewed publications
↘ Used across genetics, pharmacology, and circuit perturbation studies
↘ Provides scientific and technical foundation
for Brian AI’s decoding stack.
Without CNS-trained decoding, biodiversity-derived neurochemistry collapses into noise.
Founding Executives ↘
Eric Szelenyi, Ph.D.
Neuroscientist and platform architect. Founder of Platea and creator of the CNS-native biodiversity discovery thesis. Former faculty (UW Neurobiology & Biophysics). Leads platform strategy, translational direction, and institutional partnerships.
Simon Nilsson, Ph.D.
Creator of SimBA, the world’s most widely adopted behavioral AI platform (>2M downloads). Leads Brian AI™ architecture and scalable behavioral decoding for CNS discovery.
Scientific Advisors ↘
Trevor Robbins, Ph.D.
Global authority in behavioral pharmacology and translational CNS neuropsychopharmacology.
Sam Golden, Ph.D.
Leader in preclinical CNS disease modeling and behavioral phenotyping.
Ian Covert, Ph.D.
Expert in explainable
and interpretable machine learning for high-stakes
biological systems.
Jason Tucciarone,
MD Ph.D.
Physician-scientist focused
on psychiatric disease biology and clinical translation. Aligns Platea’ preclinical discovery pipeline with clinically meaningful signal selection.
Jaime Costales, PhD.
Leads institutional and in-region
scientific governance.
Hugo Navarrete, PhD.
National authority in ethnobotany
and biodiversity documentation
supporting discovery
prioritization.
Business Advisors ↘
Martin Akerman, Ph.D.
Advises on platform architecture
and long-term discovery strategy.
Ken Graves, MBA.
Advises on pharma partnership
design, commercialization
strategy, and global expansion.
Gary Ambrosino, MBA.
Advises on Brian AI™ platform
scaling, operational cadence
and investor-ready
growth systems.